HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via ISI Web of Science (15) Citing Articles via Google Scholar Google Scholar Articles by Mazzone, P.J. Articles by Maurer, J.R. Search for Related Content PubMed PubMed Citation Articles by Mazzone, P.J. Articles by Maurer, J.R.

The humoral immune response to influenza vaccination in lung transplant patients

¹ Dept of Pulmonary and Critical Care Medicine, The Cleveland Clinic Foundation, and ² Dept of Infectious Diseases, The Cleveland Clinic Foundation, Cleveland, OH, USA

CORRESPONDENCE: P.J. Mazone, Dept of Pulmonary and Critical Care Medicine, 9500 Euclid Ave A90, Cleveland, OH, 44195, USA. Fax: 1 2164458160

Keywords: Antibodies, cyclosporine, influenza, lung transplantation, tacrolimus, vaccination

Received: February 28, 2001
Accepted July 10, 2001

The purpose of this study was to evaluate the humoral immune response to influenza vaccination in lung transplant recipients.

Antibody levels to the three viral antigens included in the 1999–2000 trivalent influenza vaccine (A/Sydney/5/97-like (H3N2), A/Beijing262/95-like (H1N1), and B/Yamanashi/16/98) were measured before and 4 weeks postvaccination in 43 lung transplant recipients and 21 healthy adult controls. The ability to develop protective antibody levels, a serological response, and the magnitude of change in levels were assessed.

The humoral immune response to influenza vaccination was significantly lower in the transplant group for all three viral antigens. To A/Sydney, 95% of the control group and 40% of the transplant group developed protective levels (p=0.0009); to A/Beijing, 71% of the control group and 30% of the transplant group developed protective levels (p=0.004); and to B/Yamanashi, 48% of the control group and 19% of the transplant group developed protective levels (p=0.02). Those receiving cyclosporine had lower antibody responses when compared to those receiving tacrolimus (r=–0.3056, p=0.0463).

The humoral immune response to influenza vaccination in lung transplant recipients is poor. Lung transplant recipients receiving cyclosporine may have a lower antibody response than those receiving tacrolimus. Alternative prevention strategies may be needed.